Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

2H2O-based high-density lipoprotein turnover method for the assessment of dynamic high-density lipoprotein function in mice.

Kasumov T, Willard B, Li L, Li M, Conger H, Buffa JA, Previs S, McCullough A, Hazen SL, Smith JD.

Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):1994-2003. doi: 10.1161/ATVBAHA.113.301700. Epub 2013 Jun 13.

2.

Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1.

Umemoto T, Han CY, Mitra P, Averill MM, Tang C, Goodspeed L, Omer M, Subramanian S, Wang S, Den Hartigh LJ, Wei H, Kim EJ, Kim J, O'Brien KD, Chait A.

Circ Res. 2013 May 10;112(10):1345-54. doi: 10.1161/CIRCRESAHA.111.300581. Epub 2013 Mar 15.

4.
5.

Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL.

Tavori H, Su YR, Yancey PG, Giunzioni I, Wilhelm AJ, Blakemore JL, Zabalawi M, Linton MF, Sorci-Thomas MG, Fazio S.

J Lipid Res. 2015 Mar;56(3):635-43. doi: 10.1194/jlr.M056408. Epub 2015 Jan 15.

6.

Increased cholesterol efflux in apolipoprotein AI (ApoAI)-producing macrophages as a mechanism for reduced atherosclerosis in ApoAI((-/-)) mice.

Major AS, Dove DE, Ishiguro H, Su YR, Brown AM, Liu L, Carter KJ, Linton MF, Fazio S.

Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1790-5.

7.

Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity.

Murphy AJ, Funt S, Gorman D, Tall AR, Wang N.

Circ Res. 2013 Jun 21;113(1):e1-e9. doi: 10.1161/CIRCRESAHA.113.301112. Epub 2013 Apr 23.

9.

Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice.

Park TS, Panek RL, Rekhter MD, Mueller SB, Rosebury WS, Robertson A, Hanselman JC, Kindt E, Homan R, Karathanasis SK.

Atherosclerosis. 2006 Dec;189(2):264-72. Epub 2006 Feb 2.

PMID:
16458317
10.

Enhanced atheroprotection and lesion remodelling by targeting the foam cell and increasing plasma cholesterol acceptors.

Son SH, Goo YH, Choi M, Saha PK, Oka K, Chan LC, Paul A.

Cardiovasc Res. 2016 Feb 1;109(2):294-304. doi: 10.1093/cvr/cvv241. Epub 2015 Oct 20.

11.

Factors controlling nascent high-density lipoprotein particle heterogeneity: ATP-binding cassette transporter A1 activity and cell lipid and apolipoprotein AI availability.

Lyssenko NN, Nickel M, Tang C, Phillips MC.

FASEB J. 2013 Jul;27(7):2880-92. doi: 10.1096/fj.12-216564. Epub 2013 Mar 29.

12.

Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice.

Samyn H, Moerland M, van Gent T, van Haperen R, Grosveld F, van Tol A, de Crom R.

Atherosclerosis. 2009 Jun;204(2):429-34. doi: 10.1016/j.atherosclerosis.2008.10.020. Epub 2008 Oct 30.

PMID:
19100548
13.

ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels.

Trigueros-Motos L, van Capelleveen JC, Torta F, Castaño D, Zhang LH, Chai EC, Kang M, Dimova LG, Schimmel AWM, Tietjen I, Radomski C, Tan LJ, Thiam CH, Narayanaswamy P, Wu DH, Dorninger F, Yakala GK, Barhdadi A, Angeli V, Dubé MP, Berger J, Dallinga-Thie GM, Tietge UJF, Wenk MR, Hayden MR, Hovingh GK, Singaraja RR.

Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):2147-2155. doi: 10.1161/ATVBAHA.117.309574. Epub 2017 Sep 7.

PMID:
28882873
14.

A pathway-dependent on apoE, ApoAI, and ABCA1 determines formation of buoyant high-density lipoprotein by macrophage foam cells.

Yancey PG, Yu H, Linton MF, Fazio S.

Arterioscler Thromb Vasc Biol. 2007 May;27(5):1123-31. Epub 2007 Feb 15.

15.

Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.

Hambruch E, Miyazaki-Anzai S, Hahn U, Matysik S, Boettcher A, Perović-Ottstadt S, Schlüter T, Kinzel O, Krol HD, Deuschle U, Burnet M, Levi M, Schmitz G, Miyazaki M, Kremoser C.

J Pharmacol Exp Ther. 2012 Dec;343(3):556-67. doi: 10.1124/jpet.112.196519. Epub 2012 Aug 23.

16.

Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.

Castellani LW, Navab M, Van Lenten BJ, Hedrick CC, Hama SY, Goto AM, Fogelman AM, Lusis AJ.

J Clin Invest. 1997 Jul 15;100(2):464-74.

17.

Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.

Shimizu T, Miura S, Tanigawa H, Kuwano T, Zhang B, Uehara Y, Saku K.

Arterioscler Thromb Vasc Biol. 2014 Oct;34(10):2246-53. doi: 10.1161/ATVBAHA.114.303715. Epub 2014 Aug 7.

18.

High density lipoprotein turnover in patients with hypertension.

Chen YD, Sheu WH, Swislocki AL, Reaven GM.

Hypertension. 1991 Mar;17(3):386-93.

20.

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.

Diabetes. 2003 Mar;52(3):803-11.

Supplemental Content

Support Center